Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Sven Nylander"'
Autor:
Taylor S. Cohen, Elizabeth J. Kelly, Sven Nylander, Himanshu Bansal, Brett M. Jepson, Prakash Bhuyan, Magdalena E. Sobieszczyk, Ann R. Falsey
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-5 (2022)
Abstract Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222. Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation of TTS, however it is unclear if AZD1222 was responsible
Externí odkaz:
https://doaj.org/article/557651084084447887ce8ffd65240554
Publikováno v:
Cellular Physiology and Biochemistry, Vol 53, Iss 6, Pp 961-981 (2019)
Externí odkaz:
https://doaj.org/article/43dce6716dd548c787d13a50864caecf
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205707 (2018)
Accurate determination of in vivo circulating concentrations of extracellular adenosine in blood samples is challenging due to the rapid formation and rapid clearance of adenosine in blood. A blood collection protocol was developed based on direct sa
Externí odkaz:
https://doaj.org/article/8cfe5737f4284386ad3f167b2cea2b1f
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0201202 (2018)
Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly
Externí odkaz:
https://doaj.org/article/142f9b6ef4164efbb336725e916f6409
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
Autor:
Constance C. F. M. J. Baaten, Leo F. Veenstra, Rick Wetzels, Johanna P. van Geffen, Frauke Swieringa, Susanne M. de Witt, Yvonne M. C. Henskens, Harry Crijns, Sven Nylander, J. J. J. van Giezen, Johan W. M. Heemskerk, Paola E. J. van der Meijden
Publikováno v:
Haematologica, Vol 100, Iss 9 (2015)
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugr
Externí odkaz:
https://doaj.org/article/ed2daf44169f4072994404a5a4b176e4
Publikováno v:
Cardiovascular Drugs and Therapy. 36:829-840
Ticagrelor and dapagliflozin can suppress the activation of the NOD-like receptor 3 (NLRP3)-inflammasome and activate AMP-activated protein kinase (AMPK). The anti-inflammatory effects of dapagliflozin has been shown to depend on AMPK activation. Dap
Autor:
Anders Himmelmann, Sven Nylander, Maria Aunes, S. Claiborne Johnston, Carlos A. Molina, Scott R. Evans, Pierre Amarenco, Stefan James, Joachim Röther, Per Ladenvall, Mikael Knutsson, Marianne Jahreskog, Hans Denison, Yongjun Wang
Publikováno v:
Stroke. 52
Introduction: In the THALES trial, ticagrelor and aspirin was superior to aspirin alone in reducing the primary endpoint of stroke or death, and subsequent disabling strokes, but increased risk of bleeding, as expected for dual antiplatelet therapy.
Autor:
Sven Nylander, Anders Himmelmann, Joachim Röther, Per Ladenvall, S. Claiborne Johnston, Scott R. Evans, Carlos A. Molina, Marianne Jahreskog, Yongjun Wang, Mikael Knutsson, Hans Denison, Maria Aunes, Pierre Amarenco, Stefan James
Publikováno v:
Stroke
Supplemental Digital Content is available in the text.
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663a1e9b9310db37ea05b9d95f2298aa
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-458771
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-458771
Publikováno v:
Cardiovascular drugs and therapy. 34(4)
Ticagrelor, a P2Y12 receptor antagonist, and dapagliflozin, a sodium–glucose-cotransporter-2 inhibitor, suppress the activation of the NLRP3 inflammasome. The anti-inflammatory effects of dapagliflozin depend on AMPK activation. Also, ticagrelor ca
Autor:
Marco Cattaneo, Alessandra Balduini, Sven Nylander, Richard C. Becker, Christian A. Di Buduo, Anna Björquist, Eti Alessandra Femia, Robert F. Storey
Publikováno v:
Thrombosis and Haemostasis. 116:1079-1088
SummaryTicagrelor is an antagonist of the platelet P2Y12 receptor for ADP, approved for the prevention of thromboembolic events in patients with acute coronary syndrome. Previous studies showed that ticagrelor has no significant activity versus P1 re